The iShares Expanded Tech-Software Sector ETF (BATS:IGV) is down 10.5% year to date while the S&P 500 is up 10.8% and the Technology Select Sector SPDR is up 26%. That gap reflects the market pricing software as if the AI thesis has turned against it.
Own IGV and you are betting the “SaaSpocalypse” narrative, that autonomous AI agents will hollow out seat-based software, is overblown relative to what fundamentals show.
What IGV holds and how it works IGV concentrates on North American software, cloud infrastructure, and adjacent digital media names. The expense ratio is 0.39%, which is fine but not cheap. The fund earns returns through price appreciation of large-cap software equities. There is essentially no yield. You are paying for exposure to a specific business model, recurring subscription revenue with high gross margins, that the market suddenly doubts.
The doubt has real evidence. Enterprise buyers ask whether they need 50,000 Salesforce seats if an agent can do the work. Snowflake customers wonder whether AI models will bypass the data warehouse entirely.
Fundamentals versus the panic ServiceNow (NYSE:NOW | NOW Price Prediction), a top holding, reported Q4 revenue of $3.57 billion, up 21%, with Now Assist net new ACV more than doubling year over year. CEO Bill McDermott called ServiceNow “the AI control tower for business reinvention”. Yet the stock is down 27% YTD and 48% over one year.
Salesforce (NYSE:CRM) is sharper. Agentforce ARR crossed $1.2 billion, up 205% year over year, with combined Agentforce and Data 360 ARR at $3.4 billion. Q1 EPS was $3.88 against a $3.13 estimate. The stock is down 35% YTD. Snowflake (NYSE:SNOW) is the counterpoint, up 21% YTD as it reported 13,600+ accounts using its AI features and raised FY27 product revenue guidance to $5.84 billion.
The Guggenheim upgrade thesis, that the sector was punished past what numbers justify, has real support in earnings. Retail agrees. Reddit sentiment flipped in early June to “The SaaSpocalypse is over” posts on wallstreetbets, with one r/stocks thread on the software rout drawing 391 upvotes and 309 comments. IGV rallied 10% last week alone.
Real risks to consider First, concentration. IGV is heavily weighted to mega-caps, so the fund trades on how the market feels about NOW, CRM, Microsoft, and Oracle on any given day. Second, execution divergence. Check Point Software (NASDAQ:CHKP) missed its top-line estimate in Q1, a reminder that not every holding participates in AI upside. Third, opportunity cost. Over five years IGV has returned 19% against XLK’s 155%. If you wanted tech, XLK crushed the software-only slice.
Who should buy and who should pass IGV works as a sector sleeve for an investor who already owns broad market exposure, believes the AI panic on software is a repricing overshoot, and can size it at roughly 3% to 7% of a portfolio without losing sleep when it moves 10% in a week. It is a tactical opportunity dressed as an ETF. If you cannot articulate why Agentforce hitting $1.2 billion ARR matters more than the stock chart, the fund is probably not a fit for your process. XLK gives you cheaper, broader tech exposure with less single-thesis risk.
The key risk. If AI agents genuinely compress seat counts across enterprise software over the next two years, IGV’s largest holdings face structural revenue headwinds that no valuation reset fixes. The bet is that the transition monetizes rather than cannibalizes. So far earnings say monetization. The tape says cannibalization. IGV is where you take a side.
Contact [email protected] for any questions or corrections.
Germany’s seized Bitcoin stash is back at the centre of the market conversation after wallets linked to the country’s Federal Criminal Police Office moved another large tranche of BTC toward major exchanges.
For more details, visit the official Arkham platform.
TL;DR Arkham-tracked wallets tied to Germany’s BKA have continued sending Bitcoin to exchanges.The flows are being watched closely because exchange deposits can signal potential selling pressure.The story is less about one transfer and more about how much supply the market can absorb. The important detail is where the coins are going. Transfers to Coinbase, Kraken, Bitstamp, and other exchange-linked destinations are not the same as cold-storage reshuffling. They usually make traders ask whether more supply is about to hit the order books.
A Government Wallet Becomes A Market Signal State-held Bitcoin does not move like ordinary whale supply. The wallets are visible, the balances are large, and the market tends to react before anyone can say with certainty whether coins have actually been sold. That is why the German wallet has become one of the most watched addresses in crypto this week.
The selling risk comes at an awkward time for Bitcoin. Spot ETF demand has been choppy, macro traders are still watching rate-cut expectations, and older supply events such as Mt. Gox repayments are also sitting in the background. Put together, the market is dealing with a cleaner version of an old problem: even bullish structure can wobble when too much BTC appears to be heading toward exchanges at once.
What Traders Should Watch The next question is whether these transfers become actual sell orders, and whether buyers are deep enough to absorb them without a sharper move lower. Exchange inflows alone do not prove a sale has happened, but they do tighten the window between potential supply and market impact.
For now, the BKA-linked wallet is not just an on-chain curiosity. It is a live supply story, and Bitcoin traders will keep watching every move until the exchange flows slow down or the market proves it can take the pressure.
This report is based on wallet data from Arkham Intelligence.
This article was written by the News Desk and edited by Samuel Rae.
BONK DAO has confirmed that attackers drained an estimated $20 million worth of BONK tokens from its treasury through a malicious governance proposal.
The stolen funds have reportedly started moving to exchanges, prompting the project to coordinate with exchanges, the Solana Foundation, and law enforcement in an effort to recover the assets. The BONK meme coin fell over 10% on this news.
BONK Price Performance. Source: BeInCryptoBONK DAO Confirms $20 Million Governance AttackBONK DAO has become the latest victim of a high-profile decentralized governance attack after confirming that approximately $20 million in BONK tokens was drained from its treasury.
BonkDAO was the target of a malicious governance proposal resulting in an estimated $20M worth of BONK tokens being drained from the BonkDAO treasury.
During the investigation, BonkDAO identified the exchange wallets used to purchase BONK ahead of the proposal. BonkDAO is…
— BONK!!! (@bonk_inu) July 6, 2026 Follow us on X to get the latest news as it happens
According to the project’s official statement, the attacker successfully passed a malicious governance proposal, allowing treasury funds to be transferred to wallets under their control. BONK said it has already identified the exchange wallets used to accumulate voting power before the proposal was executed.
The team is now working alongside exchanges, the Solana Foundation, bridges, and law enforcement to track the stolen assets and explore recovery options.
How the Attack WorkedPreliminary on-chain analysis shared by blockchain investigators suggests the attacker purchased roughly $4 million worth of BONK to secure enough voting power for the proposal.
Once approved through BONK DAO’s governance system on Solana’s Realms platform, the proposal authorized the transfer of an estimated $20 million from the DAO treasury.
Unlike a smart contract exploit, the incident appears to be a governance attack, where token-weighted voting was used to legitimately approve a malicious treasury transaction.
“Basically $4M worth of BONK was used by the drainer to vote YES for taking $21M worth of BONK tokens from the DAO,” one expert highlighted.
Reports also indicate that portions of the stolen BONK have already begun moving to cryptocurrency exchanges, raising concerns that the attacker may attempt to liquidate the holdings.
BONK Transfers After Hack. Source: ArkhamWhat’s Next for BONK?The investigation remains ongoing, with BONK stating that recovery efforts are underway.
The incident is expected to renew industry debate over DAO governance security, particularly around safeguards such as timelocks, multisignature approvals, and treasury execution delays designed to prevent single governance proposals from draining protocol funds.
Investors will now be watching for updates on potential fund recovery, exchange actions, and whether BONK introduces governance reforms to strengthen treasury protection.
Tether has launched Alloy, a synthetic dollar product backed by Tether Gold, in a move that pushes the stablecoin issuer further beyond simple dollar tokens.
For more details, visit the official Tether platform.
TL;DR Tether has introduced Alloy and its aUSDT synthetic dollar product.The product is backed by Tether Gold (XAUt) rather than traditional cash reserves.The launch shows stablecoin design expanding into new forms of collateral. Most stablecoin stories are about whether a token is backed by dollars, Treasuries, or bank deposits. Alloy is different. It is designed around over-collateralization with liquid gold exposure, creating a synthetic dollar instrument rather than another straightforward fiat-backed token.
Why Gold-Backed Dollars Are Interesting Tether already dominates the conventional stablecoin market with USDT. Alloy suggests the company wants to build a wider collateral platform, where users can hold exposure that behaves like a dollar product while being backed by tokenized gold.
That is a more complex promise than a standard stablecoin. It introduces collateral-price dynamics, liquidation mechanics, and a different risk profile. It also shows why stablecoin issuers are becoming more like financial infrastructure companies than single-product crypto firms.
The Risk Is In The Design The appeal is clear: users get a dollar-denominated asset tied to gold collateral, potentially blending the familiarity of stablecoin units with a different reserve base. The caution is just as clear. Synthetic products need users to understand how collateral, redemptions, and market stress interact.
For Tether, Alloy is a way to test how far its brand can stretch. USDT is the liquidity engine. XAUt is the commodity-backed asset. aUSDT tries to connect the two into something more programmable. Whether traders embrace it will depend less on the headline and more on how it behaves when markets are not calm.
This article is based on information from Tether.
This article was written by the News Desk and edited by Samuel Rae.
Not financial or tax advice. PANews content is strictly educational and informational and is not investment advice, financial advice, tax advice, legal advice, or a solicitation to buy or sell any digital asset, security, or financial product. Do your own research and consult qualified advisers.
Disclosure. PANews may publish sponsored content, partner content, advertisements, affiliate links, event promotions, and market commentary involving Web3 projects, service providers, or financial products. PANews personnel, contributors, or affiliates may hold digital assets or other interests related to covered topics. See our Terms of Service.
MALVERN, Pa., July 06, 2026 (GLOBE NEWSWIRE) -- CubeSmart (NYSE: CUBE) today announced that the Company will release financial results for the three-month period ended June 30, 2026 after the market close on Thursday, July 30, 2026. An accompanying conference call will be held at 11:00 a.m. ET on Friday, July 31, 2026.
A live webcast of the conference call will be available online from the investor relations page of the Company’s corporate website at investors.cubesmart.com. Telephone participants may join on the day of the call by dialing 1 (833) 461-5787 using conference ID number 574860863. Registered financial analysts participating on the call may avoid delays by pre-registering using the following link: https://events.q4inc.com/analyst/574860863?pwd=XXrIBM1q. A replay of the webcast will be available on the Company’s website following the live event.
About the Company
CubeSmart is a self-administered and self-managed real estate investment trust. CubeSmart owns or manages 1,534 self-storage properties across the United States. According to the 2026 Self Storage Almanac, CubeSmart is one of the top three owners and operators of self-storage properties in the U.S.
The Company’s mission is to simplify the organizational and logistical challenges created by the many life events and business needs of its customers – through innovative solutions, unparalleled service, and genuine care. The Company's self-storage properties are designed to offer affordable, easily accessible, and, in most locations, climate-controlled storage space for residential and commercial customers.
For more information about business and personal storage or to learn more about the Company and find a nearby storage property, visit www.cubesmart.com or call CubeSmart toll free at 800-800-1717.
Company Contact:
Josh Schutzer
Senior Vice President, Finance
610-535-5700
The iShares U.S. Aerospace & Defense ETF (BATS:ITA) has climbed 35% over the past year and nearly 17% year to date, and the reflexive retail question is whether the run is exhausted. The more useful question is whether ITA still fits the trade you actually want to make, which is long-cycle Western rearmament.
Buying ITA is a bet that Washington keeps writing bigger checks, NATO keeps chasing its new spending pledge, and the primes keep converting backlog into cash. The rally is real. The cycle it reflects is likely not close to over.
What you actually own ITA tracks U.S. aerospace and defense equities, holds 47 positions, and manages roughly $13.5 billion in net assets. The return engine is straightforward. You collect the earnings power of the U.S. defense industrial base plus commercial aerospace recovery, weighted heavily toward the primes.
GE (NYSE:GE | GE Price Prediction) sits at 22% of the fund, RTX (NYSE:RTX) at 15%, Boeing (NYSE:BA) at 9%. Add a few more names and you have accounted for the bulk of the portfolio before the fund even reaches its 47 smaller names.
So ITA is really a concentrated bet on eight companies with a long tail of drone, space, and specialty suppliers stapled on. Names like Axon (NASDAQ:AXON) at 3.3%, Rocket Lab (NASDAQ:RKLB) at 3.5%, and Kratos (NASDAQ:KTOS) at 0.7% give you exposure to the newer weapons and space economy without dominating results.
Does the thesis hold up The macro tailwind is unambiguous. The FY 2027 Department of War request totals about $1.45 trillion, and NATO members agreed at last summer’s Hague Summit to a new 5% of GDP defense spending standard. Goldman Sachs is now flagging economic security, including the €800 billion ReArm Europe plan, as a defining 2026 megatrend. Missile inventories are depleted, drone demand is structural, and Boeing’s aircraft backlog remains multi-year.
Performance confirms the setup is working. ITA is up 137% over five years and 348% over ten, which handily beats broad industrials and matches the S&P 500 over the longer window while doing something different. That is the point of a thematic sleeve. It should express a view distinct from the index. That is the entire reason to own it.
The tradeoffs are real Start with valuation. ITA trades at roughly 38 times earnings, well above the cyclical multiples this group used to command. You are paying growth-stock prices for companies that historically traded like utilities with backlogs. Second, concentration. When GE and RTX together are more than a third of the fund, one accounting scandal or program cancellation moves the whole ETF.
Third, policy risk. Proposed rules tying buybacks and dividends to contractor performance standards, along with a CEO compensation cap, would compress the capital-return story that has helped drive multiples higher.
If concentration bothers you, SPDR S&P Aerospace & Defense (NYSEARCA:XAR) is the equal-weighted alternative and tilts more toward mid-caps and suppliers. Invesco Aerospace & Defense (NYSEARCA:PPA) sits in between. If you want the primes to do the heavy work, ITA is the cleaner expression.
The verdict ITA earns a place as a 3% to 7% thematic sleeve for investors who want direct exposure to the rearmament cycle and can tolerate the concentration in five or six defense primes. Waiting for a clean pullback is defensible given the 9% one-month move, but scaling in over several months beats trying to time a cycle backed by multi-year budget authorizations.
Investors who need income, hate cyclicality, or expect valuations to mean-revert to pre-2022 defense multiples should look elsewhere. Everyone else is looking at a first-inning trade that happens to have already scored some runs.
Contact [email protected] for any questions or corrections.
Key Takeaways Kratos Defense is expanding unmanned systems and air defense through new contracts and production investments.KTOS grew first-quarter 2026 Unmanned Systems revenues, driven primarily by XQ-58A Valkyrie activity.KTOS faces supply-chain and cost pressures, though 2026 and 2027 EPS estimates project strong growth. Kratos Defense & Security Solutions, Inc.’s (KTOS - Free Report) shares have risen 23.6% over the past year compared with the Zacks Aerospace-Defense Equipment industry’s growth of 22.6%. The company continues to hold a leading position as the U.S. Army's principal supplier of unmanned target drones, with long-term demand supported by consistent U.S. defense budget allocations.
Image Source: Zacks Investment Research
Other defense equipment stocks have shown mixed performance over the past year. While Curtiss-Wright (CW - Free Report) has gained 54.7%, AeroVironment (AVAV - Free Report) declined 20.7%. Curtiss-Wright and AeroVironment are specialized defense technology companies that benefit from U.S. military modernization and rising defense spending, rather than being prime defense contractors.
Considering Kratos Defense’s outperformance, investors might be left wondering if this is a good time to add KTOS stock to their portfolio. Let's examine the factors that contributed to the share price gain and assess the stock's investment prospects to make an informed decision.
Tailwinds for KTOS StockKratos Defense is the primary unmanned aerial target drone system provider for the U.S. Air Force, Navy, Army and several allied defense agencies. This position has led to multiple recent contracts and partnerships that are expanding its presence in the global UAS market, including a Counter-UAS award in March 2026 and teaming activity tied to the XQ-58A Valkyrie. In first-quarter 2026, Unmanned Systems revenues increased to $82.6 million from $63.1 million a year earlier, driven primarily by Valkyrie-related activity.
In July 2026, Kratos Defense received an approximate $36 million sole-source contract award for a new air defense missile system. The sole-source nature of the award indicates that Kratos Defense possesses specialized capabilities that the customer considered difficult to replace through competitive bidding, strengthening its reputation as a trusted supplier for sensitive national security programs. The contract also supports higher utilization of the manufacturing capacity that the company has been expanding in recent years, potentially improving operating leverage as production scales.
In June 2026, Kratos Defense announced its plans to significantly increase production capacity for its Spartan line of turbojet engines to support growing demand across missile and loitering munition programs. By increasing annual production capacity to 3,000 engines and investing ahead of demand through internally funded procurement of long-lead materials and supply-chain enhancements, Kratos Defense is improving its ability to deliver at scale while shortening lead times for customers.
Headwinds for KTOSKratos Defense continues to cite supply-chain disruptions and parts availability as industry issues that can delay material receipts and deliveries. Management’s 2026 outlook explicitly assumes potential manufacturing and supply-chain disruptions, parts shortages and continued cost increases. Inventoried costs increased to $225.7 million as of March 29, 2026, from $188.2 million as of 2025-end, consistent with larger lot purchases and long-lead items. Persistently higher input costs or further supply friction could pressure margins and keep cash conversion below investor expectations.
Estimates for KTOS StockThe Zacks Consensus Estimate for 2026 and 2027 earnings per share (EPS) indicates an increase of 30.91% and 42.34%, respectively, year over year.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Curtiss-Wright’s 2026 and 2027 EPS implies an increase of 14.7% and 11.7%, respectively, year over year. The consensus estimate for AeroVironment’s fiscal 2027 EPS indicates an increase of 4.5% year over year.
KTOS’ Earnings Surprise HistoryThe company beat on earnings in each of the trailing four quarters, delivering an average surprise of 22.64%.
Image Source: Zacks Investment Research
KTOS’ Return on Equity Lower Than IndustryThe company’s trailing 12-month return on equity of 4.3% is lower than the industry average of 12.47%. Return on equity, a profitability measure, reflects how effectively a company utilizes its shareholders’ funds to generate income.
Image Source: Zacks Investment Research
KTOS Stock Trades at a DiscountIn terms of valuation, KTOS’ forward 12-month price/sales (P/S) is 5.33X, a discount to the industry’s average of 14.62X.
Image Source: Zacks Investment Research
What Should an Investor Do Now?Kratos Defense continues to strengthen its leadership in unmanned systems and air defense through new contract awards, strategic partnerships, and growing demand for its advanced autonomous and missile technologies. The company is also expanding its propulsion manufacturing capabilities, positioning itself to capture rising opportunities in missile, loitering munition, and next-generation defense programs.
Investors who already own this Zacks Rank #3 (Hold) stock may consider retaining their position, considering its price performance and strong earnings growth. Given its poor ROE, new investors may wait and look for a better entry point. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Sui has crossed the $1 billion total value locked mark on DeFiLlama, giving the Move-based network a clearer claim to serious DeFi liquidity.
For more details, visit the official DeFiLlama platform.
TL;DR Sui’s DeFi TVL has moved above $1 billion, according to DeFiLlama data.Lending and native DeFi protocols are helping drive capital onto the chain.The milestone strengthens Sui’s pitch as a high-performance smart contract network. TVL is an imperfect metric, but it remains one of the easiest ways to see where capital is willing to take smart contract risk. For Sui, crossing $1 billion is a meaningful marker because it moves the chain further away from early-stage experimentation and closer to the conversation around durable DeFi ecosystems.
Liquidity Is The Real Test Fast blockchains are common. Sustainable liquidity is rarer. Users can rotate through incentive programs quickly, especially when yield campaigns are generous. The question for Sui is whether capital stays after the first wave of rewards and novelty fades.
The current growth points to rising activity in lending, trading, and native protocols. That matters because a chain needs more than one flagship app to feel alive. The healthier version of Sui’s growth story is not just that TVL crossed a number, but that more capital is being deployed across several functions.
What Comes After The Milestone The next test is depth. Sui needs liquidity that supports real usage, not just headline TVL. Stablecoin availability, reliable lending markets, strong bridges, and developer retention will decide whether this becomes a lasting DeFi base.
For now, the $1 billion level gives Sui a stronger seat at the table. Move-based chains have been fighting for attention against Ethereum L2s, Solana, and other high-throughput networks. Sui now has a clearer data point to show that capital is paying attention.
This report is based on DeFiLlama data for Sui.
This article was written by the News Desk and edited by Samuel Rae.
According to CoinGecko data, more than $1.4 billion worth of tokens will be unlocked across the cryptocurrency market during the week of January 26 to February 2, 2026. Of this amount, $154.95 million will come from cliff unlocks, where a large batch of tokens enters circulation all at once rather than through gradual distribution.
Sui prepares for the week’s largest unlockThe most significant unlock of the week is expected from Sui, with tokens worth $62.68 million about to be released. Despite this large figure, the event will increase the circulating supply by only 1.14%, suggesting that the price impact could remain minimal. Sui employs a long-term vesting schedule, which means that with each unlock, certain tokens allocated to early investors, the team, and community initiatives gradually become available for trading.
As a layer-1 blockchain operating on its own network, Sui’s token unlocks are closely monitored by the market as a gauge for potential sell pressure. However, when the new issuance represents a small fraction of total supply, it often results in negligible pressure on the charts.
While Sui stands out with a $62.68 million token unlock, the increase in circulating supply is just 1.14%, so any price impact is expected to be limited.
Medium-sized unlocks: Sign’s supply jump stands outFour projects are next in line for weekly unlocks valued between $10 million and $12 million. EigenCloud will release $11.82 million in tokens, amounting to 6.71% of its total supply. Sign will see $11.72 million unlocked.
Sign’s unlock is especially notable for its high supply ratio: the newly released tokens represent 17.61% of the total supply—the highest on this week’s list. Kamino will free up $10.51 million (6.12% of its supply), while Jupiter’s $10.15 million unlock makes up 3.95%. While Sui leads in dollar value, Sign could have a bigger relative impact due to its supply jump.
ProjectUnlock amountShare of total supplySui$62.68 million1.14%EigenCloud$11.82 million6.71%Sign$11.72 million17.61%Kamino$10.51 million6.12%Jupiter$10.15 million3.95%Lower-tier unlocks: Supply ratios take the spotlightAmong the smaller unlocks this week, Optimism will release $9.15 million in tokens, corresponding to 1.62% of its total supply. Ethena is next with a $6.73 million unlock, though this equates to a modest 0.56% impact on its circulating supply.
Sahara AI plans a $5.54 million unlock, equal to 8.30% of its total supply—making it proportionally significant. ZetaChain will unlock $3.47 million (2.10%), and Gunz will add $2.63 million worth of tokens, increasing its supply by 5.70%. As these examples illustrate, dollar amounts alone do not always tell the full story; sometimes, a smaller unlock can generate a stronger impact on supply dynamics.
Market impact: Supply ratio is more critical than amountUltimately, the most important factor in token unlocks is the proportion of new supply entering circulation and the distribution method. Cliff unlocks, which distribute tokens all at once, tend to draw more attention than those spread out in installments. This week, $154.95 million will enter the market via such group unlock events.
A high dollar figure does not automatically mean strong selling pressure—what matters more is the share of new tokens versus existing supply, and whether the distribution is sudden or gradual.
From a ratio perspective, projects like Sign and Sahara AI are particularly notable this week. While Sui leads with the largest dollar value, its modest supply increase suggests a more muted effect. Other unlocks add smaller amounts of new supply at a slower rate. Analysts caution that such developments are not, on their own, definitive sell signals.
Disclaimer: The information contained in this article does not constitute investment advice. Investors should be aware that cryptocurrencies carry high volatility and therefore risk, and should conduct their own research.
Autonomous AI agents playing games, making payments, and chatting pushed Sui's programmable tunnels to a peak of 6,086,766 TPS
Main TakeawaysAI agents and users battled across games, payments, and chat using "programmable tunnels," offchain channels that settle to Sui mainnet when closed.Sui hit a peak of 6,086,766 TPS on July 4, 2026, over six times the experiment's 1 million TPS target.The peak was roughly 20 times higher than Sui's prior benchmark of 297,000 TPS, set in a controlled testing environment.On Saturday, July 4, 2026, Sui processed the highest number of transactions per second ever recorded on its network during a public livestream experiment open to anyone. Using an explorer built for the event, participants logged in with their Gmail address (thanks to Sui primitive zkLogin) and watched AI agents battle head-to-head across games, payments, and chat. The network peaked at 6,086,766 TPS at approximately 12:30 p.m. ET, more than six times the goal and roughly 20 times Sui's previous maximum-TPS benchmark of 297,000 TPS, set in a controlled testing environment.
The throughput was made possible through "programmable tunnels," offchain payment and state channels that settle to Sui mainnet when closed. After signing in with zkLogin, participants received a test token, MTPS, to use during the experiment. Gas was sponsored throughout, so no prior SUI holdings were required. From there, users and AI agents opened tunnels with one another to play games like blackjack and "Quantum Poker," draw on a shared canvas, chat, and transact, all gaslessly and offchain, with every closed channel mutually cosigned and independently verifiable onchain.
“We proved that programmable tunnels aren't just about payments,” said Kostas Chalkias, Chief Cryptographer and Co-Founder at Mysten Labs. “This is agent-to-agent commerce, competitive gaming, and prediction markets running gaslessly at massive scale. A company's trading agent could play chess or poker against another company's agent millions of times without touching the base chain. Consider real-world utility: you could lock funds offchain so someone without internet access, in an earthquake or a blackout, can still pay for groceries the moment they're near a signal again. Right now there are only four or five proven product-market fits in crypto: stablecoins, DeFi, payments, prediction markets. I think programmable tunnels just opened the door to a fifth.”
What's nextMysten Labs and the Sui hacker team plan to build on the experiment with additional capabilities, including confidential transfers via Nautilus, tunnels supporting more than two participants, and agent-to-agent prediction markets. To watch how it unfolded live, check out the recorded livestream.
Alex Van de Sande, a co-founder of the Ethereum Name Service (ENS), proposed Monday that the ENS DAO delegate 5 million ENS tokens from its dormant community treasury to individual participants.
Alex Van de Sande, a co-founder of the Ethereum Name Service (ENS), proposed Monday that the ENS DAO delegate 5 million ENS tokens from its dormant community treasury to individual participants, a step he said would end the DAO's reliance on what he called “just a 1-of-1 multisig.”
“Currently, one delegate has enough quorum to not only execute any proposal, but also to outvote the next 50 other delegates,” Van de Sande said in the proposal, in an apparent reference to ENS co-founder Nick Johnson.
Van de Sande filed the idea as a formal draft, "Reform DAO governance by delegating 5M ENS tokens," in the Meta-Governance section of the ENS DAO's discourse forum. In a post on X, he said participants would not own or be able to sell the delegated tokens, which belong to the DAO, and floated adding another 5 million tokens next year, an undelegation trigger after six months of inactivity, and a full sunset of the arrangement after two years.
Van de Sande said the proposal draws on unclaimed supply from ENS's original airdrop five years ago, which set aside half its tokens as a "community treasury" to be distributed over five years. That window has now lapsed with little of the allocation distributed, he said.
Part of a Wider FightThe proposal follows weeks of conflict over control of ENS DAO's treasury and governance. On June 19, ENS Labs COO Katherine Wu published a temp-check proposal to shift the DAO's operational wallet, ENS holdings and Karpatkey-managed Endowment to a five-seat ENS Foundation board, as The Defiant reported.
Three days later, Johnson said he would self-delegate his ENS to back the measure, a move delegates said gave him effective control of the outcome. Rotki founder Lefteris Karapetsas wrote on the forum that Johnson had "delegated ~50% of the voting supply to himself, essentially becoming the DAO," and Security Council member Brantly Millegan called the proposal "the equivalent of treasury capture by ENS Labs," The Defiant reported.
The dispute widened in late June when Johnson, using that same delegated voting power, blocked an onchain vote to renew the DAO's Security Council, a multisig empowered to cancel malicious proposals already in the timelock queue. Johnson controls an estimated 3.26 million ENS tokens, roughly half of all ENS currently delegated to any address. Christoph Jentzsch, who wrote code for the original 2016 "The DAO," responded by proposing on X that ENS DAO dissolve itself outright, calling the DAO "broken," The Defiant reported.
Both the Foundation temp check and the Security Council renewal remain unresolved. Van de Sande's plan would not change that dispute directly — it draws on a separate, dormant pool of DAO-held tokens — but it lands amid an active debate over whether ENS's governance concentrates too much power in one delegate.
ENS co-founder Alex Van de Sande put forward a proposal on Monday to delegate 5 million ENS tokens from the project’s dormant community treasury directly to individual participants. The move, he said, would end the DAO’s dependence on what he characterized as “just a 1-of-1 multisig.”
A governance crisis months in the making The proposal didn’t materialize out of nowhere. ENS DAO has been mired in governance disputes throughout June and July 2026, with blocked votes and escalating tensions between community factions. At the center of the controversy sits Nick Johnson, ENS’s other co-founder, who reportedly holds approximately 50% of the active voting supply through self-delegated tokens.
The disputes have also touched on attempts to expand the ENS Foundation’s role, which some community members interpreted as a potential “governance attack.”
Advertisement
What 5 million tokens would actually change The ENS DAO originally received an allocation of 50 million ENS tokens. Of those, 5 million were claimed early in 2021 during the project’s initial distribution phase, leaving a substantial portion sitting in treasury wallets.
Van de Sande’s proposal would take 5 million tokens, roughly 10% of the original allocation, and delegate them to individual governance participants. The tokens would remain in the treasury, but their voting power would be assigned to active participants. The ENS DAO treasury valuations range from approximately $88 million in liquid assets to over $350 million in total worth when including the underlying ETH-based endowment managed by Karpatkey.
Katherine Wu, another prominent figure in ENS governance circles, has been involved in the ongoing discussions.
What this means for ENS holders and DAO watchers Van de Sande’s framing of the current setup as a “1-of-1 multisig” is a deliberate provocation, designed to highlight that the current governance apparatus has the trappings of decentralization without the substance. A multisig wallet typically requires multiple signers to approve a transaction. A 1-of-1 multisig is just a regular wallet with extra branding.
Delegating treasury tokens to active participants, rather than selling them or letting them sit idle, represents a middle path between hoarding assets and diluting existing holders. However, redistributing voting power means existing large holders would see their relative influence diluted — the same stakeholders who would need to approve the proposal are those whose power it would reduce.
Disclosure: This article was edited by Editorial Team. For more information on how we create and review content, see our Editorial Policy.
, /PRNewswire/ -- Vectra Bank Colorado is pleased to welcome Ty Aslin to the Executive team as Director of Commercial Banking. In this role, Ty will lead the organization focused on companies with revenues greater than $10MM. He will be responsible for market strategy, driving sales performance, senior credit oversight, and further strengthening Vectra Bank's relationships across the Colorado business community.
Ty brings more than 25 years of banking leadership experience at several of the nation's largest banks. He has a strong track record of building high-performing teams and driving sustained growth spanning commercial, retail, and private banking. Throughout his career, Ty has consistently been recognized as a top performer, earning multiple President's Club and Pinnacle awards for revenue growth, client acquisition, and portfolio performance.
Ty is also deeply engaged in the community, having previously served on the Colorado Bankers Association Board and the Metro Denver Economic Development Board of Governors. He supports financial literacy and business mentorship initiatives, and is currently pursuing new board positions as a representative of Vectra Bank.
About Vectra
With assets of $4 billion, Vectra Bank Colorado is a proactive, customer-focused organization dedicated to real relationship banking. Part of the Zions Bancorporation family of banks, Vectra serves Colorado's small, middle-market and corporate business clients with 34 locations throughout Colorado, and one in Farmington, New Mexico. Zions Bancorporation, N.A. is included in the S&P 400 Mid-Cap and NASDAQ Financial 100 indices (NASDAQ: ZION). The bank's website address is www.vectrabank.com.
SAN JOSE, Calif.--(BUSINESS WIRE)--Rambus Inc. (Nasdaq: RMBS), a premier chip and silicon IP provider making data faster and safer, today announced that it will hold a conference call on Monday, July 27, 2026, at 2:00 p.m. Pacific Time to discuss its second quarter fiscal year 2026 results. This call will be webcast and can be accessed via Rambus' website at investor.rambus.com. A replay will be available following the call on the Rambus Investor Relations website or for one week at the followi.
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
The proposed transactions may contain terms that could limit superior competing offers.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
NEW YORK, July 06, 2026 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Dana Incorporated (NYSE: DAN)’s sale to Eaton Corporation plc. Upon closing of the Proposed Transaction, Dana shareholders will own approximately 49.9% of the combined company. If you are a Dana shareholder, click here to learn more about your legal rights and options.
Element Solutions Inc (NYSE: ESI)’s sale to Solstice Advanced Materials, Inc. for $10.00 in cash and 0.500 shares of Solstice common stock for each Element share. Upon closing of the Proposed Transaction, Element shareholders are expected to own approximately 44% of the combined company. If you are an Element shareholder, click here to learn more about your rights and options.
Nuvalent, Inc. (NASDAQ: NUVL)’s sale to GSK plc for $124.00 per share in cash. If you are a Nuvalent shareholder, click here to learn more about your rights and options.
Boundless Bio, Inc. (NASDAQ: BOLD)’s merger with Serapha Bio, Inc. Upon closing of the proposed transaction, Boundless Bio shareholders are expected to own approximately 3.7% of the combined company. If you are a Boundless Bio shareholder, click here to learn more about your rights and options.
On behalf of shareholders, Halper Sadeh LLC may seek increased consideration, additional disclosures and information, or other relief and benefits.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
One World Trade Center
85th Floor
New York, NY 10007
(212) 763-0060 [email protected] [email protected]
https://www.halpersadeh.com
NEW YORK--(BUSINESS WIRE)--Workiva Inc. (NYSE:WK), a leading, AI-powered platform for trust, transparency, and accountability, today announced that it will release financial results for the second quarter ended June 30, 2026 following the close of the market on August 4, 2026. The company will host a conference call and a live webcast to discuss its financial results. The conference call will begin at 5:00 p.m. Eastern Time on August 4, 2026, and can be accessed by dialing 1-833-630-1956 (U.S.
New York, New York and New Orleans, Louisiana--(Newsfile Corp. - July 6, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until August 28, 2026 to file lead plaintiff applications in a securities class action lawsuit against Hub Group, Inc. ("Hub" or the "Company") (NASDAQ: HUBG), if they purchased or otherwise acquired the Company's securities between April 28, 2023, and May 11, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the Northern District of Illinois.
Cannot view this video? Visit:
https://www.youtube.com/watch?v=aqHdidapNT0
What You May Do
If you purchased securities of Hub as above and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-hubg/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by August 28, 2026.
>>>CLICK HERE for more information
About the Lawsuit
Hub Group and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On February 5, 2026, the Company disclosed that its financial statements and reports for the first three quarters of 2025 should not be relied upon due to "an error that resulted in the understatement of purchased transportation costs and accounts payable in the first nine months of 2025" and that it planned to restate the statements. On this news, the price of Hub Group shares fell approximately 18%, from $51.33 per share on February 5, 2026 to $41.96 on February 6, 2026.
Then, on May 12, 2026, the Company disclosed that it had "identified certain transactions that were prematurely or incorrectly recognized or not adequately supported," causing its 2023 and 2024 annual reports filed with the SEC to be "materially misstated," such that they should no longer be relied upon, and "expect[ed] to conclude that it did not maintain effective disclosure controls and procedures and internal control over financial reporting for each of the years ended December 31, 2024 and 2023." On this news, the price of Hub Group shares fell an additional 13%, from $41.86 per share at close on May 11, 2026 to $36.62 on May 12, 2026.
The case is Lawler v. Hub Group, Inc., et al, 26-cv-07596.
>>>To Learn More, Click HERE
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.
TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services
To learn more about KSF, you may visit www.ksfcounsel.com.
>>>For More Information about the case, Click HERE
NEW YORK, July 06, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating The Ensign Group (NASDAQ: ENSG) (“Ensign” or the “Company”) for potential violations of the federal securities laws.
On June 8, 2026, Hunterbrook published a detailed short-seller report alleging that the company engaged in systemic quality-measure gaming, falsified care-quality data, and improper related-party billing across its skilled nursing operations. Following this news, the price of Ensign stock fell significantly, causing millions of dollars in shareholder losses.
Then, on June 11, 2026, Muddy Waters Research published a short report on Ensign Group, alleging possible Medicare and Medicaid fraud via a scheme to rent licenses of administrators of skilled nursing facilities who are not actually managing the facilities, potentially in violation of the False Claims Act. This news caused the price of Ensign stock to drop even further.
“Our investigation concerns whether the company and its executives provided investors with accurate and complete information about the company,” said Andrea Farah, Lowey Dannenberg, P.C., Partner and Head of the firm’s securities practice.
If you suffered a loss in Ensign securities and wish to participate, check your eligibility through Lowey’s case management platform, https://claimmagic.com/cases/the-ensign-group. Alternatively, you can contact our attorneys Andrea Farah ([email protected]) at (914)733-7256 or Vincent R. Cappucci Jr. ([email protected]) at (914)733-7278.
About Lowey Dannenberg
Lowey Dannenberg is a national firm representing institutional and individual investors who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has previously recovered billions of dollars on behalf of investors.
Attorney Advertising
Contact
Lowey Dannenberg P.C.
44 South Broadway, Suite 1100
White Plains, NY 10601
Tel: (914) 733-7256
Email: [email protected]
If you sold common stock of ChampionX between February 29, 2024 and April 1, 2024 and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at [email protected] or by telephone at (212) 355-4648.
Click here to participate in the action.
NEW YORK, July 06, 2026 (GLOBE NEWSWIRE) --
What’s Happening?
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against ChampionX Corporation (“ChampionX” or the “Company”) (NASDAQ:CHX) in the United States District Court for the Southern District of New York on behalf of all persons and entities who sold common stock of ChampionX between February 29, 2024 and April 1, 2024, both dates inclusive (the “Class Period”).Investors have until July 14, 2026 to apply to the Court to be appointed as lead plaintiff in the lawsuit. What are the Allegation Details?
According to the lawsuit, defendants throughout the Class Period failed to disclose material information, which artificially deflated the price of ChampionX common stock. On February 29, 2024, ChampionX received an unsolicited non-public offer from Schlumberger Limited to purchase all the outstanding shares of ChampionX for $36.70 per share. On March 7, 2024, Schlumberger raised its offer to $37.80 per share. The lawsuit alleges that while these offers were on the table and unknown to the investing public, ChampionX was repurchasing its common stock at market prices significantly below the prices offered by Schlumberger. ChampionX had an obligation to disclose that it had received a formal acquisition offer from Schlumberger or abstain from purchasing ChampionX stock from unsuspecting investors. During the Class Period, ChampionX's average stock price was $33.32 per share. On Tuesday, April 2, 2024, during pre-market hours, ChampionX disclosed the merger with Schlumberger. The merger eventually closed on July 16, 2025, with Schlumberger acquiring ChampionX for $40.58 per share. What are my Next Steps?
If you purchased or otherwise acquired ChampionX shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities, derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation. The firm has a nationwide practice and routinely handles cases in both federal and state courts. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn.
Americké akciové indexy vykázaly v úvodní seanci po prodlouženém víkendu kladnou bilanci v čele s technologickým Nasdaqem (+1,12 %). Širší index S&P500 přidal 0,72 % a Dow Jones 0,29 %. Mírný zisk registrovaly také dluhopisy vyjma nejdelších maturit. Výnos 10letého vládního bondu se posunul na 4,47 % z pátečních 4,48 %. V červeném uzavřely drahé kovy. Zlato odepsalo 0,3 % na 4162 USD/oz, stříbro končilo slabší o 0,64 % na 62 USD/oz. V energetickém sektoru se dařilo zemnímu plynu, který zpevnil téměř o 1,7 % na 3,25 USD/mmbtu. Ropa končila beze změny na 68,7 USD/barel.
Závěrečné hodnoty:
Index Dow Jones 0,29 % na 53055,91 b.
Index Nasdaq Composite 1,12 % na 26121,16 b.
Index S&P 500 +0,72 % na 7537,43 b.
Nejsilnější sektory S&P Změna Nejslabší sektory S&P Změna Sektor komunikací +1,6 % Zdravotní péče -1,2 % Informační technologie +1,3 % Utility -1,1 % Nezbytná spotřeba +1 % Reality -0,9 % Nejsilnější akcie S&P Změna Nejslabší akcie S&P Změna Arista Networks (ANET) +8,3 % O'Reilly Automotive (ORLY) -6,7 % Western Digital (WDC) +7,1 % AutoZone (AZO) -6,4 % Tesla (TSLA) +6,7 % Alexandria Real Estate Equities (ARE) -5,2 % Advanced Micro Devices (AMD) +6,6 % Constellation Brands (STZ) -4,9 % NetApp (NTAP) +6,1 % Tractor Supply (TSCO) -4,8 % Zdroj: Reuters
New York, New York and New Orleans, Louisiana--(Newsfile Corp. - July 6, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in PicS N.V. ("PicS" or the "Company") (NASDAQ: PICS) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors of PicS who were adversely affected if they purchased the Company's Class A common stock in and/or traceable to its January 30, 2026 initial public offering (the "IPO"). This action is pending in the United States District Court for the Southern District of New York.
Cannot view this video? Visit:
https://www.youtube.com/watch?v=FQIEqld_vCU
Follow the link below to get more information and be contacted by a member of our team:
https://www.ksfcounsel.com/cases/nasdaqgs-pics/
PicS investors should contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nyse-ses/?prs=nf to learn more.
CASE DETAILS: According to the Complaint, PicS and certain of its executives are charged with failing to disclose material information in the Offering Documents, violating federal securities laws. The alleged false and misleading statements and omissions include, but are not limited to, that: (i) in December 2025, the Company determined that its credit assessment procedures were deficient and required enhancement; (ii) following implementation of revised procedures, the Company reclassified approximately R$590 million of exposures from Stage 2 to Stage 3, resulting in an incremental ECL charge of R$88 million for the quarter ended December 31, 2025; (iii) the Company experienced an undisclosed Stage 3 formation rate exceeding 7% in the fourth quarter of 2025, materially departing from the historical trends disclosed in the offering documents; (iv) the offering documents materially overstated the effectiveness of PicS N.V.'s credit models, user data, and underwriting and risk-monitoring capabilities; and (v) prior to the IPO, PicS N.V.'s expansion into riskier business lines had led to deteriorating credit quality, increased default and impairment risk, and adverse financial and operational trends that were expected to continue worsening and materially impact the Company's business and financial results.
The case is FirstFire Global Opportunities Fund, LLC v. PicS N.V., No. 26-cv-04793.
WHAT TO DO? If you invested in PicS and suffered a loss during the relevant time frame, you have until August 4, 2026 to request that the Court appoint you as lead plaintiff; however, your ability to share in any recovery does not require that you serve as a lead plaintiff.
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.
TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services
To learn more about KSF, you may visit www.ksfcounsel.com.
, /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Commvault Systems, Inc. ("Commvault" or "the Company") (NASDAQ: CVLT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of CVLT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: April 29, 2025 to January 26, 2026
DEADLINE: July 17, 2026
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Commvault touted its ARR growth while disregarding important factors such as type of sale when developing its growth guidance. Based on these facts, Commvault's public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate.
WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
, /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Commvault Systems Inc. ("Commvault" or the "Company") (NASDAQ: CVLT).
IF YOU SUFFERED A LOSS ON YOUR COMMVAULT INVESTMENTS, CLICK HERE BEFORE JULY 17, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT
What Is The Lawsuit About?
The complaint filed alleges that, between April 29, 2025 and January 26, 2026, Defendants failed to disclose to investors that: (1) Commvault knew or recklessly disregarded the impact that different types of sales would have on its ARR growth; (2) the variation in net ARR growth is strongly based on the type of sale Commvault is making, thus, the Company's projected net new ARR should not have been determined without properly factoring in sale type; and (3) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
Charles Linehan, Esq.,
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: [email protected]
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.
If you inquire by email, please include your mailing address, telephone number and number of shares purchased.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact Us:
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles, CA 90067
Charles Linehan
Email: [email protected]
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.
SAN FRANCISCO, July 06, 2026 (GLOBE NEWSWIRE) -- Hagens Berman, a national shareholder rights firm, alerts investors in Commvault Systems, Inc. (NASDAQ: CVLT) that a newly filed securities class action lawsuit has expanded the alleged class period. The lawsuit now covers investors who purchased or otherwise acquired Commvault securities between January 28, 2025, and January 26, 2026, inclusive.
Hagens Berman is investigating the claims pled in the pending litigation and encourages Commvault investors who suffered substantial losses to submit your losses now.
Expanded Alleged Class Period: Jan. 28, 2025 – Jan. 26, 2026
Lead Plaintiff Deadline: July 17, 2026
Visit: www.hbsslaw.com/investor-fraud/cvlt
Contact the Firm Now: [email protected]
844-916-0895
Expanded Scope of Allegations
The new suit, City of Fort Lauderdale Police and Firefighters' Retirement System v. Commvault Systems, Inc., et al., extends the start of the alleged fraud period from April 29, 2025, back to January 28, 2025. This expansion captures a broader range of investor activity and expands the claims brought against the company and its senior executives regarding their business disclosures.
Focus of CVLT Securities Class Action Litigation:
The litigation alleges that Defendants misrepresented and failed to disclose that:
Commvault’s competitive positioning was materially weaker than Defendants had represented to investors;Due to the undisclosed increase in competition, Commvault was forced to make significant concessions on price and contract duration for its software licenses;As these concessions became unsustainable, SaaS became a larger portion of the Company’s sales mix;The increasing mix of SaaS sales, which carry shorter term durations and lower ASPs, negatively impacted the Company’s margin and NNARR; andAs a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. The truth allegedly emerged before markets opened on January 27, 2026, when Commvault announced its third-quarter fiscal year 20261 financial results. Commvault disclosed NNARR in constant currency of $39 million, missing analysts’ expectations of approximately $45 million. Chief Accounting Officer Danielle Abrahamsen (“CAO Abrahamsen”) revealed that the mix of SaaS deals increased to “70%” during the quarter and highlighted that “landing these customers at a 2 to 3x smaller ASP than software . . . does have a significant impact on ARR.”
On this news, the price of Commvault common stock fell $40.23 per share, or about 31%, to close at a price of $89.13 per share on January 27, 2026.
HBSS Investigation
“We continue to investigate whether Commvault misled investors about its operational performance and financial reporting during the alleged expanded class period, as the new complaint contends” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation of the pending claims.
If you invested in Commvault and have substantial losses, or have knowledge that will assist the firm’s investigation, submit your losses now.
If you’d like more information and answers to frequently asked questions about the Commvault case and the firm’s investigation, read more »
View our latest video summary of the allegations: youtu.be/YILiBV90q2w
Whistleblowers: Persons with non-public information regarding Commvault should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].
About Hagens Berman
Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.
Allegro MicroSystems, Inc. is positioned for multiyear growth via automotive, data center, and industrial robotics markets, but shares reflect much of the near-term upside. Key ALGM growth drivers include higher content per vehicle, data center transition to 800-VDC, and an inflection point in robotics/physical AI expected in CY27. ALGM's balance sheet has improved, with leverage down to 0.65x net debt/aEBITDA, supporting strategic M&A, debt reduction, and opportunistic share repurchases.
When a stock hits a 52-week high, that's a great sign the business is doing well. And when it hits a new all-time high, then you know the market is really excited about what's ahead for the business. But at the same time, there can also be concerns that its valuation is getting too steep, and that there may be plenty of downside risk.
Vertex Pharmaceuticals (VRTX +0.27%) is a top healthcare company and a leader in cystic fibrosis treatments. Its stock has been doing exceptionally well this year, with gains of around 17%, far above the S&P 500's returns of about 10% thus far. And amid the rise in value, the stock has hit a new all-time high. Is it too late to buy shares of Vertex, or could there still be more gains ahead?
Image source: Getty Images.
Investors are hopeful for much more growth ahead for Vertex In its most recent earnings results, Vertex's numbers didn't look all that impressive; the pharma company's sales were up just 8%, totaling roughly $3 billion for the period ending March 31. And its growth rate has been declining in recent years.
But the hope for investors is that in the long run, there may be much more growth to come, with gene therapy Casgevy still in its early rollout. Non-opioid pain medication Journavx was also approved just over a year ago, and thus, Vertex still has some levers to pull on to drive its growth rate higher in the future. Plus, it has many ongoing trials that could unlock many more opportunities in the future.
Today's Change
(
0.27
%) $
1.42
Current Price
$
529.46
Is Vertex's stock still worth buying right now? Vertex is currently trading at around 31 times its trailing earnings, which is far higher than the S&P 500 average of 25. Even based on the company's expected future earnings, the stock may be a bit expensive as its price-to-earnings-growth (PEG) multiple is around 2.0, which factors in the growth that analysts expect from the business over the next five years. When a stock's PEG is around 1.0 or lower, it's considered a good buy, but with Vertex being well above that, this may be a sign that there may be too much future growth already priced into the stock's value right now. It may rise higher, but it may also be approaching a peak.
Although Vertex's business looks promising and it has plenty of growth potential, it's not a stock I'd buy today because of its high valuation, as that can drastically impact future returns. There are better and more reasonably priced growth stocks to choose from today.
BOSTON & SAN DIEGO--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, for a total equity value of approximately $10.0 billion, or approximately.
A sign hangs in front of the world headquarters of Vertex Pharmaceuticals in Boston, Massachusetts, U.S., October 23, 2019. REUTERS/Brian Snyder/File Photo Purchase Licensing Rights, opens new tab
CompaniesJuly 6 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab will buy Crinetics Pharmaceuticals (CRNX.O), opens new tab for a total equity value of about $10 billion, the companies said on Monday.
Shares of Crinetics more than doubled in extended trading, while those of Vertex were marginally down.
Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.
The acquisition gives Vertex access to Palsonify, which was approved by the U.S. Food and Drug Administration in September 2025 to treat adults with acromegaly, a rare hormonal disorder caused by excess growth hormone. The companies said the once-daily oral therapy has shown early commercial momentum since launch.
Crinetics’ experimental drug, atumelnant, is in late-stage development for congenital adrenal hyperplasia, or CAH, a rare genetic disorder affecting the adrenal glands.
The companies said Palsonify and atumelnant could together generate more than $5 billion in peak annual sales. Vertex expects the deal to add immediately to revenue growth and become accretive to non-GAAP operating income in 2029.
Vertex will pay $85 per Crinetics share, the companies said, with the deal expected to close in the third quarter of 2026.
Reporting by Puyaan Singh in Bengaluru; Editing by Jonathan Ananda
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Key Takeaways IonQ launched Clavis XG Multiplex to make quantum security deployable across metro fiber networks. IONQ's Clavis XG Multiplex uses existing network infrastructure to reduce long-term cryptographic risk. IonQ launched InSAR capabilities for millimeter-precision ground deformation monitoring. IonQ (IONQ - Free Report) is strengthening its commercial portfolio beyond quantum computing by expanding into quantum cybersecurity and space-based geospatial intelligence. In line with this, the company introduced Clavis XG Multiplex, marking a new addition to its Clavis XG Quantum Key Distribution (“QKD”) portfolio designed to make quantum security deployable across metropolitan fiber networks.
Clavis XG Multiplex enables high-performance, physics-based key distribution on a customer’s existing network infrastructure without requiring operators to redesign, isolate or dedicate optical networks for quantum security. The result provides a cost-effective way to reduce long-term cryptographic risk across network segments as broader post-quantum cryptography (PQC) migration progresses across the enterprise.
IonQ also commercially launched Interferometric Synthetic Aperture Radar (InSAR) capabilities through its space missions line. The offering enables millimeter-precision ground deformation monitoring with fully automated tasking and data delivery. It enables customers to detect and track physical changes on the Earth's surface with a frequency and scale never previously offered by a commercial SAR provider.
Peer UpdateRigetti (RGTI - Free Report) recently announced the general availability of its 108-qubit quantum system, Cepheus-1-108Q, marking a significant step forward in its scaling roadmap. The system represents the company’s largest modular architecture to date, built using its proprietary chiplet-based design. Rigetti is demonstrating progress in scaling quantum hardware while maintaining performance benchmarks such as 99.1% median two-qubit gate fidelity and 99.9% single-qubit fidelity.
Quantum Computing Inc. (QUBT - Free Report) is steadily expanding its footprint in applied quantum technologies. The company secured a contract from the National Institute of Standards and Technology to develop thin-film lithium niobate photonic integrated circuits, highlighting its growing capabilities in advanced photonics. Additionally, QUBT won a subcontract linked to NASA Langley Research Center to develop quantum-based techniques for removing solar noise from space-based LiDAR data, reinforcing its role in next-generation aerospace innovation.
IONQ’s Price PerformanceOver the past year, IONQ’s shares have gained 8.6% compared with the industry’s 221.9% growth.
Image Source: Zacks Investment Research
Expensive ValuationIonQ currently trades at a forward 12-month price-to-sales (P/S) of 54.58X compared with the industry median of 4.45X.
Image Source: Zacks Investment Research
IONQ Stock Estimate TrendIn the past 30 days, its loss per share estimate for 2026 has moved south to $1.07.
Image Source: Zacks Investment Research
IonQ currently has a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Energy Transfer stands out among energy infrastructure plays, providing investors stability with fee-based earnings predictability. ET has outperformed sector peers since April, as investors rotated back. As the energy infra trade now regains buying momentum after the earlier year's pro-cyclical fervor, ET is well positioned to benefit from this market rotation. The massive, multi-trillion-dollar AI CapEx buildout through the decade is expected to drive sustained demand for ET's diversified pipeline infrastructure.
ROCKLAND, Mass.--(BUSINESS WIRE)--Independent Bank Corp. (Nasdaq Global Select Market: INDB), parent of Rockland Trust Company, announced the following details for its second quarter 2026 earnings release and conference call: Earnings Release: Thursday, July 16, 2026, after the market close Conference Call (held via Webcast): Friday, July 17, 2026, at 10:00 AM Eastern Time How to Join Webcast: Participants may join the webcast by registering prior to the call via this link: https://events.q4inc.
Non-exclusive license agreement for the development and commercialization of novel post-operative light adjustable PCIOL technologiesCollaboration aims to combine best-in-class PCIOL optics with first-in-class platform to enable fine-tuning of visual outcomes after cataract surgery ALISO VIEJO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and RxSight, Inc. (NASDAQ: RXST), an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced a non-exclusive collaboration to jointly develop adjustable presbyopia-correcting intraocular lenses (PCIOLs).
Under the collaboration, the companies will be innovating on their respective platforms – RxSight's post-operative light-adjustable technology and Alcon's PCIOL optical designs – and combining them to create a co-developed technology that enables surgeons to fine-tune visual outcomes for their cataract patients who choose a PCIOL.
“Our leading PCIOLs have helped millions of patients reduce or eliminate the need for glasses after cataract surgery,” said David J. Endicott, Chief Executive Officer of Alcon. “Together with RxSight’s technology, we have the opportunity to develop tunable PCIOLs, giving surgeons even greater confidence to refine outcomes after surgery.”
“We are excited to work with Alcon to provide patients greater access to outcomes customized to their needs after surgery,” said Ron Kurtz, President and Chief Executive Officer of RxSight. “This collaboration underscores our belief in the importance of adjustability and will help accelerate its expansion across a wider base of patients.”
As part of the agreement, RxSight will receive a $60 million upfront payment to begin development. RxSight could receive up to an additional $140 million in payments as development and regulatory milestones are met. Under the agreement, Alcon will lead global commercialization, while RxSight will be responsible for development and manufacturing and receive royalties on net sales.
About Alcon
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries and territories each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.
About RxSight, Inc.
RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®/LAL+®, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.
Forward-looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. All statements in this press release that are not purely historical are forward-looking statements, including, without limitation, statements regarding: potential payments that may be received by us in connection with the collaboration, including potential milestone payments and royalties; and RxSight’s and Alcon’s respective rights and obligations under the collaboration agreement, a description of which (including material terms and conditions) may be found in the Current Report on Form 8-K filed of even date herewith with the Securities and Exchange Commission (SEC). The forward-looking statements contained herein are based upon our current expectations and involve assumptions that may never materialize or may prove to be incorrect. These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including, without limitation, uncertainty as to whether the anticipated benefits and opportunities of the proposed collaboration may be realized or make take longer to realize or may cost more than expected; risks of unexpected hurdles, costs or delays; challenges in technology transfer and manufacturing; challenges inherent in new product candidate development, including obtaining regulatory approvals; challenges associated with collaborating with third parties, including intellectual property, operational, financial and other risks; uncertainty of commercial success for new products; the ability of RxSight and Alcon to successfully execute their respective strategic plans; and other risks that may be found in the section entitled Part II, Item 1A (Risk Factors) in the Quarterly Report on Form 10-Q for the period ended March 31, 2026, filed with the Securities and Exchange Commission (SEC) on May 6, 2026, and other documents that RxSight files from time to time with the SEC. These forward-looking statements are made as of the date of this press release, and RxSight assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Connect with us on
https://www.facebook.com/rxsight/
https://www.linkedin.com/company/rxsight/
https://www.instagram.com/rxsight/
http://www.youtube.com/@rxsight
HONOLULU--(BUSINESS WIRE)--Bank of Hawai‘i Corporation (NYSE: BOH) (the “Company”) will release second quarter 2026 financial results on Monday, July 27, 2026 before the market opens and hold its quarterly conference call at 2:00 p.m. Eastern Time (8:00 a.m. Hawai‘i Time) on the same day. The live call, including a slide presentation, will be accessible on the investor relations link of the Company's website, www.boh.com. The webcast link is https://register-conf.media-server.com/register/BIbf8.
, /PRNewswire/ -- Universal Health Services, Inc. (NYSE: UHS) announced today that it will report results for its second quarter ended June 30, 2026, after the market closes on Monday, July 27, 2026. There will be a conference call for investors and analysts on Tuesday, July 28, 2026, at 9:00 a.m. Eastern Time.
A live webcast and audio archive of the call may be accessed through the investor relations section of the company's website at ir.uhs.com. To participate via telephone, please register in advance using this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call.
About Universal Health Services
One of the nation's largest and most respected providers of hospital and healthcare services, Universal Health Services, Inc. (NYSE: UHS) has built an impressive record of achievement and performance, growing since its inception into a Fortune 300 corporation. Headquartered in King of Prussia, PA, UHS has approximately 101,500 employees. Through its subsidiaries, UHS operates 30 acute care hospitals, more than 340 behavioral health facilities and approximately 170 outpatient and other facilities, an insurance offering, a physician network and various related services located in 40 states, Washington, D.C., Puerto Rico and the United Kingdom.
[url="]The Law Offices of Frank R. Cruz[/url] announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired
, /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Peabody Energy Corporation ("Peabody" or "the Company") (NYSE: BTU) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of BTU during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: October 14, 2024 to May 4, 2026
DEADLINE: August 24, 2026
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Peabody gave investors the impression it could provide accurate guidance on the growth of production at its Centurion mine. In fact, the Centurion mine suffered from multiple delays. Based on these facts, Peabody's public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate.
WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]
, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Peabody Energy Corporation ("Peabody" or "the Company") (NYSE: BTU) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between October 14, 2024 and May 4, 2026, inclusive (the "Class Period"), are encouraged to contact the firm before August 24, 2026.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Peabody falsely led investors to believe it could reliably predict the ramp-up and growth of its Centurion mine. The Company suffered wide-ranging issues and delays at the Centurion mine. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Peabody investors suffered damages.
Join the case to recover your losses
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Peabody Energy Corporation (“Peabody” or the “Company”) (NYSE: BTU) common stock between October 14, 2024 to May 4, 2026, inclusive (the “Class Period”). Peabody investors have until August 24, 2026 to file a lead plaintiff motion.
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN PEABODY ENERGY CORPORATION (BTU), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.
Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at [email protected], by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.
What Happened?
On March 30, 2026, Peabody issued a press release lowered guidance concerning its Centurion mine’s first quarter 2026 output due to mining commissioning challenges.
On this news, Peabody’s stock price fell $3.82, or 9.7%, to close at $35.68 per share on March 30, 2026, thereby injuring investors.
Then, on May 5, 2026, Peabody disclosed that it had failed to complete its goal to fully ramp-up Centurion by March 2026 and that it was cutting guidance related to full year metallurgical segment volumes to reflect the increased cost and substantial volume decrease.
On this news, Peabody’s stock price fell $1.52, or 5.7%, to close at $25.00 per share on May 5, 2026, thereby injuring investors further.
What Is The Lawsuit About?
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Peabody’s overly optimistic March 2026 Centurion ramp-up date and promises regarding the Company’s inflated guidance, fell short of reality when numerous issues at Centurion caused a significant delay to the mine’s ramp-up and Peabody’s first quarter metallurgical segment volumes; and (2) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
Contact Us To Participate or Learn More:
If you purchased Peabody common stock, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Telephone: (215) 638-4847
Email: [email protected],
Visit our website at: www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
LAUSANNE, Switzerland & SAN JOSE, Calif.--(BUSINESS WIRE)--Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced that it expects to release first quarter fiscal year 2027 financial results on Tuesday, July 28, 2026 at 1:00 p.m. Pacific Daylight Time (PDT) and 10:00 p.m. Central European Summer Time (CEST). There will be a videoconference to discuss these results at 1:30 p.m. PDT and 10:30 p.m. CEST on the same day. A livestream of the event will be available on the Logitech corporat.
Key Takeaways CoStar launched its flagship platform in France after acquiring BureauxLocaux and Business Immo. The French platform covers 290,000 properties, 385,000 tenants and 90,000 active availabilities. CoStar expects Q2 2026 revenues of $922M-$932M, with the Zacks Consensus Estimate implying 18.95% growth. CoStar Group (CSGP - Free Report) shares have plunged 55.4% year to date (YTD), significantly underperforming the Zacks Computer & Technology sector's return of 14.7%. The drop reflects investor concerns surrounding elevated investments in Homes.com and stiff competition against the likes of Zillow, Redfin and Realtor.com as well as a challenging commercial real estate market. These factors have weighed on near-term profitability despite CSGP’s continued double-digit revenue growth.
However, CoStar remains focused on expanding its global real estate ecosystem. On Thursday (July 2), CoStar launched its flagship CoStar platform in France, expanding its commercial real estate intelligence platform to one of Europe’s largest commercial real estate markets. The launch builds on the company's acquisitions of BureauxLocaux and Business Immo, together with years of investment in proprietary local research to create one of the most comprehensive commercial property databases in France.
The platform provides investors, brokers, owners, occupiers and lenders with a single interface to curated property records, live property availabilities, verified sales and lease comparables, exclusive industry news and real-time market analytics. At launch, the French platform covers more than 290,000 commercial properties, 385,000 commercial tenants, 90,000 active property availabilities, 75,000 lease activities and sales comparables along with more than 134 market and submarket reports on key markets such as Greater Paris, Lyon and Marseille.
The launch in France strengthens CoStar’s global network. The company has more than 320,000 commercial real estate professionals who subscribe to its platform, offering French customers access to international commercial property markets and its subscribers the ability to evaluate investment opportunities in France seamlessly. The launch is expected to deepen customer engagement, expand cross-border subscription opportunities and strengthen CoStar's long-term recurring revenue growth.
International Expansion Strengthens CoStar's Growth StoryThe France expansion supports CoStar’s strategy of becoming the leading global commercial real estate information and analytics provider. The company has invested more than $5 billion over the past four decades to build its proprietary real estate database, which now tracks approximately 9 million properties, 8 million commercial tenants, 2 million property owners, 7 million lease activities, 5 million sales comparables and more than 15,000 market reports worldwide.
CoStar continues to expand its commercial real estate platform through new data products and AI-powered solutions. The addition of CoStar Rent Benchmark, CoStar New Homes and CoStar Debt Solutions broadens the platform's capabilities across property analytics, residential construction intelligence and commercial lending. These offerings, combined with the company's growing international footprint, are expected to strengthen CoStar's competitive position, deepen customer engagement and support long-term recurring subscription revenue growth.
CSGP Offers Strong Q2 GuidanceCoStar's expanding commercial real estate platform and growing global footprint position the company well for sustained top-line growth. The company expects second-quarter 2026 revenues to be in the range of $922-$932 million.
The Zacks Consensus Estimate for second-quarter 2026 revenues is pegged at $929.32 million, indicating year-over-year growth of 19%.
The consensus mark for earnings per share is pegged at 28 cents per share, which has remained unchanged over the past 30 days. The figure implies a year-over-year increase of 64.7%.
CSGP’s Zacks Rank & Other Stocks to ConsiderCurrently, CoStar Group carries a Zacks Rank #2 (Buy).
Digital Turbine (APPS - Free Report) , Dell Technologies (DELL - Free Report) and Flex (FLEX - Free Report) are some other top-ranked stocks that investors can consider from the broader Zacks Computer and Technology sector. Digital Turbine, Dell Technologies and Flex sport a Zacks Rank #1 (Strong Buy) each at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
APPS shares have rallied 154.2% in the year-to-date period. The long-term earnings growth rate for Digital Turbine is pegged at 18.98%.
DELL shares have surged 213.2% in the year-to-date period. The long-term earnings growth rate for Dell Technologies is pegged at 26.35%.
Shares of FLEX have gained 126.5% in the year-to-date period. The long-term earnings growth rate for Flex is pegged at 45.76%.
LONDON, ENGLAND: Dana Strong, CEO Sky set to acquire ITV Media & Entertainment Division. 2026 in London, England. (Photo by Eamonn McCormack/Getty Images)
Getty Images
Sky has agreed to acquire ITV Media & Entertainment—the ITV channels, the ITVX streaming service and the advertising business that funds them—for up to £1.6 billion. The deal, announced Monday, would fold the UK’s biggest commercial broadcaster into the UK’s biggest pay-TV operator.
The price is the story. ITV’s own announcement values the division at roughly six times its 2025 earnings. That is what the market now pays for the whole of flagship commercial British television: its mass reach, its news operation and the Channel 3 licenses that run to 2034.
For ITV, this was less a choice than a conclusion. For Sky, it is a bet that reach is the last scarce asset in British broadcasting.
What Sky Is Actually BuyingThe asset is audiences. ITV reaches around 40 million people every week, and ITVX has grown to 16.5 million monthly active users. Combined with Sky, the two account for roughly 20% of all in-home video viewing in the UK—second only to the BBC and ahead of YouTube.
That reach comes with the advertising machine attached. A single sales house spanning free-to-air, pay TV and two streaming services is a scale proposition Sky could not build alone, plus around £200 million in annual cost synergies by year three. The channels stay free-to-air with public service obligations intact. Completion, expected in the second half of 2027, still depends on regulatory approval.
MORE FOR YOU
What ITV Keeps And What Sky Gives UpITV is not selling the family silver. ITV Studios—the production business behind its biggest dramas and formats—stays with shareholders as a standalone listed company, underpinned by a content supply agreement guaranteeing a minimum £2.1 billion of spend from the combined Sky-ITV business between 2028 and 2032.
Sky surrenders something too. Love Productions, its in-house producer valued at £200 million, crosses to ITV Studios as part of the consideration. And ITV plans to return approximately £950 million of the proceeds to shareholders, around 25p per share.
A Sale Born Of NecessityThe harder question is whether ITV still had a credible standalone answer for broadcasting. A decade of declining linear audiences and a share price that never recovered its mid-2010s levels left the company subscale against competitors that outspend ITV many times over.
The realistic options were three: shrink and manage decline, merge with another subscale European broadcaster or separate the growing business from the declining one. Only separation returned cash to shareholders and gave Studios a global stage. The six-times multiple is the cost of waiting this long to choose.
A Champion Assembled Inside A SpinoffThere is one more wrinkle. A week before signing, Comcast announced it would spin off Sky together with NBCUniversal into a standalone media company—a separation that follows a familiar playbook. The UK’s new commercial television champion is being assembled inside a business its own parent has already decided should stand apart.
ITV concluded that reach and content are worth more apart. Comcast reached the same verdict about media and the pipes that carry it. Sky is betting the opposite: in a fragmented market, aggregated reach is still worth buying.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Marvell Technology (NASDAQ:MRVL | MRVL Price Prediction) looks compelling because the market is only now pricing in a durable second act in custom AI silicon. The stock has nearly tripled year to date, but the fundamental picture keeps outrunning the multiple.
Marvell designs the analog, mixed-signal, and photonic infrastructure that hyperscalers use to move data around AI clusters. Data center is now 76% of revenue, up from a business that was a grab bag of storage, networking, and automotive parts. The automotive Ethernet unit sold to Infineon for $2.5 billion has been recycled into optical interconnect (Celestial AI) and chiplet packaging (XConn). The playbook mirrors Broadcom (NASDAQ:AVGO). Sell the picks and shovels, and let NVIDIA (NASDAQ:NVDA) fight the merchant GPU war.
The custom silicon flywheel The bull case rests on the XPU pipeline. Management flagged over 50 new custom AI design opportunities across more than 10 customers, and Reuters reported Marvell expects custom chip revenue to top $10 billion by fiscal 2029. Broadcom’s custom accelerator business is the comp, trading at a $1.71 trillion market cap. Marvell sits at roughly $214.58 billion. If Marvell captures even a slice of that ASIC pie, the runway is long.
Q1 FY2027 revenue hit $2.418 billion, up 27.6% year-over-year, with data center up 11% sequentially. Free cash flow more than doubled to $483.1 million. CEO Matt Murphy told investors “We are seeing exceptional AI-related bookings, and as a result, we are significantly raising Marvell’s revenue outlook for both fiscal 2027 and fiscal 2028.” Guidance calls for 35% YoY growth next quarter.
The bear case Custom silicon revenue is lumpy and concentrated among a handful of hyperscalers. Any one can vertically integrate or dual-source to Broadcom on the next node. Marvell’s CEO acknowledged customers “may be pursuing multiple paths” on XPU supply. GAAP net income collapsed 80.4% year-over-year last quarter on a $331.8 million contingent consideration charge, and stock-based comp climbed to $207.6 million. Insiders have logged 129 recent transactions, net selling.
Trailing P/E is 86x, forward P/E is 67x. Broadcom, growing faster on the bottom line, trades at a forward P/E of 20x. Any hiccup in the lead 3nm XPU program, expected to enter production in calendar 2026, triggers a violent rerating.
The wait-and-see case The wait-and-see stance has merit. The story is right, but MRVL is already up 251% over the past year and has pulled back 13% in the last month. Waiting for Q2 FY27 against the $2.70 billion revenue and $0.93 EPS guide is reasonable. If the custom XPU ramp confirms, patience costs upside. If it slips, patience saves you 30%.
The same investor newsletter that told subscribers to buy Amazon in 2002, Netflix in 2004, and Nvidia in 2005 still publishes two new stock picks every month. Over 23 years, Motley Fool's Stock Advisor has more than quadrupled the S&P 500. New members get this month's picks, the Top 10 Rankings, and a 30-day money-back guarantee. Click here to unlock their next top stocks while new members are still being accepted.
The numbers MRVL trades at $251 against a consensus analyst target of $249.33, implying the stock has slightly overshot Wall Street’s average view. The rating breakdown, 7 Strong Buy, 31 Buy, 5 Hold, 0 Sell, 1 Strong Sell, shows sentiment has already turned. Year to date the stock is up 188.99% against an S&P 500 posting a small single-digit gain, one of the widest spreads in the semiconductor group.
Why Marvell looks compelling at $256 At $251, Marvell looks compelling. The path to appreciation runs through the 3nm XPU ramp with the lead US hyperscaler and the second announced XPU program that Murphy said is already engaged on the follow-on generation architecture. Add the NVIDIA NVLink Fusion partnership and the Celestial AI photonics stack, and Marvell monetizes every layer of the AI rack except the GPU itself.
The risk-reward is asymmetric even at this valuation. If custom chip revenue reaches the $10 billion by fiscal 2029 target, today’s forward multiple compresses fast even without further expansion. A hyperscaler defecting to Broadcom is real, but it would take multiple quarters to show up in bookings, and management says the customer set is widening beyond the top four.
What invalidates the thesis? A cut to FY28 outlook, a lost socket, or gross margin stepping down as low-margin custom volume scales faster than higher-margin optical business. Watch Q2 FY27 gross margin against the 58.25% to 59.25% guide. If it holds and revenue clears $2.7 billion, this stock has room to Broadcom’s neighborhood.
Marvell has stopped being the smaller cousin and started running the custom silicon playbook that turned Broadcom into a trillion-dollar company.
If You'd Bought Amazon When the Motley Fool Said To…In September 2002, Stock Advisor told subscribers to buy Amazon. In December 2004, Netflix. In April 2005, Nvidia. The newsletter still publishes two new stock picks every month — and over 23 years, has more than quadrupled the S&P 500. Here's how to get this month's picks:
- Join Stock Advisor for one year, with a 30-day money-back guarantee
- Get this month's two new picks — plus the Top 10 Rankings and the full historical pick list
- Read the analysis, decide for yourself, and trade through your own brokerage
Five years from now, you'll probably wish you'd bought this month's picks. Don't miss them.
Key Takeaways DexCom sees CGM expansion, G7 15 Day adoption and global growth supporting future performance.DXCM expanded non-insulin coverage, while low CGM penetration leaves room for multiyear growth.DexCom faces risks from CMS timing, input cost inflation and a maturing U.S. CGM market. DexCom, Inc. (DXCM - Free Report) is well positioned for growth in the coming quarters, supported by the significant potential of the continuous glucose monitoring (CGM) market. A strong first-quarter 2026 performance and a robust international foothold are expected to contribute further. Risks related to stiff competition persist.
This Zacks Rank #3 (Hold) company’s shares have gained 7.3% so far this year against the industry’s 12.4% decline. The S&P 500 Index has gained 9.4% in the same time frame.
DXCM, a renowned medical device company and provider of CGM systems, has a market capitalization of $27.49 billion. It projects a 23.6% growth rate over the next five years and anticipates maintaining a strong performance going forward.
DexCom’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 9.37%.
Image Source: Zacks Investment Research
Let’s delve deeper.
Positive DriversType 2 Non-Insulin Expansion Represents Untapped Growth Opportunity: DexCom's biggest long-term catalyst remains the rapid expansion of CGM into the type 2 diabetes population not using insulin. During the quarter, the company expanded commercial coverage to more than 7 million non-insulin lives through the addition of Prime Therapeutics and reiterated that CMS reimbursement may start soon.
Management also expects the upcoming randomized controlled trial to reinforce the strong real-world evidence showing meaningful A1c reductions, potentially accelerating payer adoption globally. Since only about 30% of currently covered patients are using CGM, penetration remains low despite expanding reimbursement. If Medicare coverage eventually follows commercial payers, DexCom would gain access to millions of additional patients, creating a durable multiyear volume growth engine rather than a short-term sales catalyst.
G7 15-Day Launch Strengthens Competitive Position: The successful rollout of the Dexcom G7 15 Day system represents more than a routine product refresh. Longer wear time, improved sensor algorithms and better reliability are already driving higher customer satisfaction, stronger new patient starts and conversion of existing users.
Management expects nearly 50% of the installed base to migrate to the 15-day platform by year-end, improving customer retention while supporting manufacturing efficiencies. The launch also reinforces DexCom's ability to compete on product innovation rather than pricing, an increasingly important differentiator as the CGM market becomes more competitive.
Combined with upgraded adhesive technology, AI-powered software enhancements and Smart Basal functionality, DexCom is building a comprehensive ecosystem that could improve customer value while strengthening physician preference over competing platforms.
Robust Growth in International Markets: International operations continue to diversify DexCom's growth profile, reducing dependence on the mature U.S. diabetes market. International revenues grew 26% reportedly and 17% on an organic basis, driven by reimbursement expansion in markets such as France and Canada, while management highlighted additional payer wins expected throughout 2026.
Rather than relying on a single flagship product, DexCom is tailoring multiple products (including Stelo and a new CGM platform) to different reimbursement systems and customer segments across Europe and Asia-Pacific. This portfolio strategy is helping the company win tenders, convert previously exclusive contracts into dual-source agreements and steadily gain market share. As reimbursement expands globally, international markets could remain one of DexCom's fastest-growing businesses over the next several years.
RisksUncertain CMS Reimbursement Decisions: Although management repeatedly expressed confidence that Medicare reimbursement for non-insulin type 2 patients is inevitable, the timing remains entirely outside the company's control. Management acknowledged that CMS could impose eligibility requirements before approving coverage, while investors continue to view the decision as a major binary catalyst.
Because the opportunity represents one of DexCom's largest future growth drivers, any prolonged regulatory delay would postpone patient adoption, physician prescribing and revenue acceleration. Even if coverage is eventually approved, implementation timing and reimbursement criteria could influence the pace of uptake. Consequently, a meaningful portion of DexCom's long-term growth narrative still depends on external reimbursement decisions that management cannot directly influence.
Rising Input Cost Inflation Threatens Further Margin Expansion: Despite reporting excellent first-quarter profitability, DexCom deliberately maintained its gross margin guidance because of growing geopolitical uncertainty. Management estimates that rising oil prices, resin costs and freight expenses could create a 50-100 basis point gross margin headwind during the remainder of 2026.
Since CGM sensors rely heavily on petroleum-derived materials and global logistics, sustained commodity inflation could offset manufacturing productivity gains. While operational execution currently remains strong, prolonged geopolitical disruptions affecting shipping routes or raw material availability may pressure production costs and delay further margin expansion. As DexCom continues ramping up manufacturing capacity globally, maintaining cost discipline will become increasingly important for preserving profitability.
U.S. CGM Market Growth May Moderate as Penetration Matures: Although DexCom reported a global record for new patient additions, management acknowledged that U.S. patient starts were only close to a record, highlighting the increasingly mature nature of the domestic CGM market. Several analysts questioned whether overall U.S. market growth is slowing as major reimbursement expansions become less frequent.
Management's guidance also assumes continued coverage gains and sustained patient acquisition momentum throughout the year. If physician adoption slows or newly covered populations convert more gradually than anticipated, domestic revenue growth could remain below historical double-digit levels. This makes continued innovation, broader reimbursement and higher patient retention increasingly critical for sustaining DexCom's long-term growth trajectory.
Estimate TrendDexCom has witnessed a positive estimate revision trend for 2026. In the past 60 days, the Zacks Consensus Estimate for 2026 earnings per share has moved north 1 cent to $2.57.
The consensus mark for the company’s second-quarter revenues is pegged at $1.3 billion, indicating an 11.9% improvement from the year-ago quarter’s reported number. The consensus estimate for second-quarter earnings is pinned at 61 cents per share, implying an improvement of 25% year over year.
Stocks to ConsiderSome better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and Intuitive Surgical (ISRG - Free Report) .
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted earnings per share (EPS) of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry’s 12.5% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.26%.
West Pharmaceutical, currently carrying a Zacks Rank #2, reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.
WST has an estimated long-term earnings growth rate of 13.9% compared with the industry’s 9.6% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.37%.
Intuitive Surgical, carrying a Zacks Rank of 2 at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.
ISRG has a long-term estimated growth rate of 14.3% compared with the industry’s 12.5% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
If a stock is down 50%, it would need to double to just get back to where it was before its decline. It's a tall task, but it also demonstrates just what kind of upside a beaten-down stock could have if it's able to get back to where it was after a sell-off.
The big question, of course, is whether it can recover, because declines like that don't just happen for no reason. Lululemon Athletica (LULU 2.37%) has lost almost that much during just the first six months of the year. At the mid-way point, it was down an incredible 45%.
With the company in the midst of a CEO transition, could it be worth taking a chance on this struggling apparel stock?
Image source: Getty Images.
The business faces a tough road ahead The problem with Lululemon's business is simple to explain, but hard to fix. The growth has virtually evaporated for this once-top growth stock. When it reported earnings last month, the company's comparable growth rate on a constant-dollar basis was just 2%. That's a far cry from what it used to generate in the past, when double-digit growth was not a problem at all.
The fix, however, is by no means easy. New CEO Heidi O'Neill is taking over in September and has decades of experience at another apparel company that's recently been struggling, Nike. Lululemon's trendy products are not as trendy anymore. Part of it may be due to consumers pushing back on high-priced items, a rise in competition (particularly from online retailers), or both. That's why fixing the issue isn't going to be easy, regardless of who's in charge.
Today's Change
(
-2.37
%) $
-2.81
Current Price
$
115.63
The stock is cheap, but it comes with plenty of uncertainty Lululemon's stock is at multi-year lows. It's around the levels it was at in 2018. And it's trading at just nine times its trailing earnings. However, even that's not enough to convince investors that it's worth buying, because there are serious concerns about how competitive it may be in the long run, and whether what's worked for it in the past will be able to work in the future.
There's virtually no reason to expect a turnaround for the stock in the second half, as it can take years for a new CEO to fix a struggling business, and even then, it's not a guarantee. Nike's new CEO has been trying to turn the business around for almost two years, and it's hard to make the case that it's in much better shape today. The problems go much deeper than what management may be able to control, and that's why I wouldn't expect Lululemon's stock to turn around anytime soon, and things could still get worse before they get better.
David Jagielski, CPA has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Nike. The Motley Fool recommends Lululemon Athletica Inc. The Motley Fool has a disclosure policy.
Investors in Prestige Consumer Healthcare Inc. (PBH - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Oct. 16, 2026 $45 Call had some of the highest implied volatility of all equity options today.
What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.
What do the Analysts Think?Clearly, options traders are pricing in a big move for Prestige Consumer Healthcare shares, but what is the fundamental picture for the company? Currently, Prestige Consumer Healthcare is a Zacks Rank #5 (Strong Sell) in the Medical – Products industry that ranks in the Bottom 31% of our Zacks Industry Rank. Over the last 60 days, no analyst increased the earnings estimates for the current quarter, while two have dropped their estimates. The net effect has taken our Zacks Consensus Estimate for the current quarter from $1.05 per share to 89 cents in that period.
Given the way analysts feel about Prestige Consumer Healthcare right now, this huge implied volatility could mean there’s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.
DeXe price extended its rally on Sunday after breaking above a key technical resistance level, with growing investor interest pushing the AI-focused governance token to its highest price in months.
Summary
DeXe price jumped more than 15% after strong on-chain activity and renewed interest in AI governance tokens fueled buying. A technical breakout and short squeeze helped propel DEXE above key resistance toward multi-month highs. Traders are now watching whether DEXE can hold above its breakout zone and challenge the $30 psychological level. According to crypto.news price data, DeXe (DEXE) price climbed more than 15% to an intraday high of $28.09 on July 6, marking its strongest daily performance in weeks. The rally came as CoinGecko highlighted DeXe as one of the best-performing AI-focused cryptocurrencies over the past week, drawing renewed attention to the protocol’s governance and decentralized autonomous organization ecosystem.
The surge also coincided with record on-chain activity. Blockchain data showed all-time highs in whale transactions, new wallet creation, and active addresses, suggesting both large investors and retail participants were accumulating the token.
Because a substantial share of DEXE’s supply remains locked in protocol treasuries, ecosystem allocations, and DAO-controlled wallets, relatively limited exchange liquidity amplified the impact of the buying pressure and accelerated the move higher.
Why is DeXe outperforming the broader crypto market? Beyond project-specific catalysts, DeXe also benefited from a notable shift in the macroeconomic backdrop. A weaker-than-expected U.S. Nonfarm Payrolls report released on July 3 strengthened expectations that the Federal Reserve could adopt a more accommodative stance in the coming months.
Falling Treasury yields and a softer U.S. dollar subsequently improved sentiment across risk assets, encouraging capital to rotate back into cryptocurrencies and decentralized finance projects.
Unlike many altcoins that struggled throughout June, DeXe entered the rebound with strong protocol fundamentals. The project currently supports more than 100 decentralized autonomous organizations while securing roughly $1.7 billion in total value locked, giving investors exposure to both AI governance infrastructure and the expanding DAO sector.
As traders searched for projects backed by measurable on-chain activity rather than speculation alone, DEXE emerged as one of the primary beneficiaries.
Derivatives positioning likely added further momentum to the rally. As the token cleared several technical resistance levels, traders holding leveraged short positions were forced to cover, creating additional buy pressure that complemented the growing spot demand. The combination of organic accumulation and forced liquidations helped accelerate the move beyond the previous resistance zone.
What does the DEXE chart suggest next? The daily chart shows DeXe confirming a powerful continuation breakout after spending several sessions consolidating around the $22-$24 region. Sunday’s rally pushed the token to a fresh multi-month high near $28 while producing one of the strongest bullish candles of the current uptrend, with buyers maintaining control into the session close.
DeXe daily price chart — July 6 | Source: crypto.news The broader trend also remains firmly constructive. DEXE continues to trade well above its 20-, 50-, 100-, and 200-day simple moving averages, which remain aligned in a classic bullish configuration. The Aroon indicator further reinforces the strength of the trend, with Aroon Up reading 100% and Aroon Down at 0%, indicating that buyers continue to dominate price action.
That said, the rally has become increasingly extended. DEXE now trades roughly 30% above its 20-day moving average, a gap that could encourage short-term profit-taking after such a rapid advance.
If buyers maintain control, the next major psychological target sits near $30, followed by the 2021 highs around $32. On the downside, the former breakout zone between approximately $24 and $25 represents the first important support area, while a deeper pullback could bring the rising 20-day moving average near $21 back into focus.
Disclosure: This article does not represent investment advice. The content and materials featured on this page are for educational purposes only.
